Market Context — Why This Technology, Why Now

The increasing complexity of biologics and gene editing tools demands sophisticated delivery systems that minimize off-target effects and maximize therapeutic payload uptake. Regulatory bodies are also pushing for safer drug profiles, making low-toxicity delivery a key differentiator. This technology directly addresses these pressures, enabling pharmaceutical companies to meet stringent safety standards while unlocking the full potential of novel therapies, driving market growth in precision medicine.

Key Competitive Advantages
01

Significantly enhances intracellular delivery efficiency, maximizing therapeutic effects compared to conventional DDS.

02

Dramatically reduces cytotoxicity by mitigating the toxicity of the membrane-damaging segment Z, expanding clinical application potential.

03

Applicable to diverse target substances, including nucleic acids, proteins, and pharmaceuticals, strongly supporting next-generation biopharmaceutical development.

Market Opportunity
Pharmaceutical & Biotech
$33.5B globally (AI est.)
Active R&D investment in gene therapies and nucleic acid drugs makes high-efficiency, low-toxicity DDS an indispensable foundational technology for improving development success rates.
Major pharmaceutical companies developing biologics Gene therapy startups Contract Research Organizations (CROs)
Regenerative Medicine
$10B globally (AI est.)
Reliable delivery of target substances for gene introduction into stem cells or immune cells in cell therapy directly maximizes therapeutic effects.
Cell therapy developers Stem cell research institutes Biomanufacturing companies
Research Reagents & Tools
$10B globally (AI est.)
The introduction of various molecules into cells is essential for basic research and drug screening, and this technology could significantly enhance research efficiency.
Life science tool providers Academic research laboratories Drug discovery service companies
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a peptide complex structure and its method for efficient and low-toxicity intracellular delivery of various substances. Its broad claims, validated against numerous prior art references, and successful navigation through rigorous examination, including overcoming a rejection, indicate a robust and defensible intellectual property asset.

Competitive White Space

This patent primarily covers the peptide complex structure and its delivery function. White space exists in developing novel conjugation chemistries for specific payloads or optimizing the peptide for targeted delivery to particular cell types or organs.

Economic Impact
~$5M/year estimated opportunity cost reduction per company (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming an average 1.5-year reduction in new drug development time from preclinical to early clinical stages, a company with an annual R&D budget of ~$33.5M (AI est.) could save ~$5M (AI est.) in annual opportunity costs. Furthermore, this technology's reduced cytotoxicity and enhanced delivery efficiency could improve clinical trial success rates by 5%, potentially contributing ~$33.5M (AI est.) in annual revenue for a drug with a post-launch market size of ~$650M (AI est.).

Speed to Market
4× faster than in-house development
This technology has a proven licensing track record, indicating established market validation and progress towards practical application. Licensees can bypass initial peptide complex design and optimization, integrating a validated technological foundation directly into their R&D. With the basic framework complete, companies can commence with target substance application and safety evaluation phases, significantly accelerating time to market.
Competitive Positioning

X: Intracellular Delivery Efficiency
Y: Cytotoxicity Risk Reduction

Business Models & Applications
🤝 DDS Technology Licensing
License this technology to pharmaceutical development companies and research institutions, facilitating its integration into their drug pipelines to generate royalty revenue.
🔬 Collaborative Research & Development
Expand the technology's application scope through joint R&D focused on specific disease areas or target substances, aiming for co-development of new therapeutics.
🧪 Contract DDS Development Services
Offer custom DDS design, development, and evaluation services for client companies' nucleic acids, proteins, and pharmaceuticals using this technology.
Adjacent Application Opportunities
🧪 Cosmetics & Beauty
Enhanced Transdermal Absorption of Active Ingredients
This peptide complex could be applied to efficiently deliver anti-aging compounds and active ingredients in serums deep into the skin. This would enable the development of cosmetic products with significantly higher efficacy than conventional formulations, potentially boosting market share by 10-15%.
🍔 Functional Foods
Improved Cellular Absorption of Nutrients & Bioactives
The technology could serve as a carrier to enhance the absorption efficiency of orally ingested functional ingredients like vitamins, minerals, and polyphenols from gastrointestinal cells. This could lead to the development of supplements and functional foods that deliver higher efficacy at lower doses, capturing a segment of the ~$50B global nutraceutical market.
🔬 Research Reagents
High-Efficiency Intracellular Delivery Reagent Kits
This technology could be offered as high-efficiency, low-toxicity reagent kits for research institutions to introduce target molecules like nucleic acids and proteins into cells. Compatible with a wide range of cell types, it would contribute to streamlining gene function analysis and drug screening, potentially cutting research time by 25%.
Integration Roadmap — Estimated 17-Month Deployment
Phase 1: Technology Evaluation & Prototype Design
Duration: 4 months
Evaluate the applicability of this technology for the licensee's target substances, design optimal peptide complex prototypes, and conduct small-scale synthesis and evaluation.
Phase 2: Target Substance Application & Optimization
Duration: 9 months
Using the designed prototypes, conjugate with the licensee's specific target substances (nucleic acids, proteins, etc.), and optimize intracellular delivery efficiency and cytotoxicity.
Phase 3: Preclinical Trials & Scale-up Review
Duration: 4 months
Conduct in vitro and in vivo preclinical trials with the optimized peptide complex and perform preliminary reviews for large-scale manufacturing.
Technical Feasibility
This peptide complex technology can be manufactured using existing peptide synthesis and purification facilities, requiring no special new equipment investment. It integrates easily into a licensee's current R&D infrastructure. Various chemical modification techniques can be used for target substance conjugation, indicating low technical hurdles. The prior licensing success further confirms its high technical feasibility.
Success Scenario
Implementing this technology could potentially double the intracellular delivery efficiency of nucleic acid drugs and gene therapies for intractable diseases, compared to conventional non-viral carriers. This could lead to shorter development periods and increased clinical trial success rates, estimated to reduce time-to-market by up to 1.5 years. Ultimately, this could enable earlier delivery of innovative treatments to a greater number of patients.
Patent Record
APPLICATION NO.
特願2021-535396
REGISTRATION NO.
7716101
FILING DATE
2020/07/29
GRANT DATE
2025/07/23
EXPIRATION DATE
2040/07/29
PATENT HOLDER
国立大学法人京都大学
Examination History
2023年05月25日
出願審査請求書
2024年08月06日
拒絶理由通知書
2024年11月28日
意見書
2024年11月28日
手続補正書（自発・内容）
2025年03月05日
拒絶査定
2025年06月05日
手続補正書（自発・内容）
2025年06月12日
審査前置移管
2025年06月17日
審査前置移管通知
2025年07月08日
特許査定
2025年07月08日
審査前置登録